Perspectives

Drug Pipeline Quarterly Update: December 2020

Drugs in review, drugs with expiring patents, generic availability and more.

December 30, 2020

These quarterly pipeline wrap-ups include new molecular entity approvals, drugs with approvable status from the FDA, potential blockbuster drugs and the dates of expected FDA approval, names of top selling brand-name drugs with generic availability in the past 12 months and names of top selling brand-name drugs that have patents expiring soon.

December 2020 Quarterly Traditional Pipeline Update
December 2020 Quarterly Specialty Pipeline Update

About Prime Therapeutics

Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization serving health plans, employers and government programs. Prime is collectively owned by 19 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans. Magellan Rx Management LLC, a Prime Therapeutics LLC Company, is a pioneer in specialty and medical drug management and a leader in serving public sector state government programs. Together Prime and Magellan Rx provide a wide range of clients with solutions that bridge the distance between medical and pharmacy management. For more information visit primetherapeutics.com and magellanrx.com or follow us on X (Twitter) at @Prime_PBM and @Magellan_Rx.

Related news

Perspectives

April 25, 2024

Clinical News: April 2024

Your monthly source for drug information highlights

Read More

Perspectives

April 25, 2024

Drug Approvals Monthly Update: April 2024

This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals…

Read More

Perspectives

April 25, 2024

Drug Approvals Quarterly Update: April 2024

This wrap-up provides a review of newly approved drugs, recent drug launches, new…

Read More
View all news